GlaxoSmithKline Royalties Come Under Scrutiny

Law360, New York (September 20, 2006, 12:00 AM EDT) -- Massachusetts-based biopharmaceutical company Avant Immunotherapeutics Inc. said on Wednesday that GlaxoSmithKline has been paying the lower of two royalty rates on its sales for a rotavirus vaccine in Australia and several European countries under a license agreement between the two companies dating back to 1997.

GlaxoSmithKline told Avant that the vaccine, Rotarix, is not covered by the licensed patents in Australia and the other European countries, the biopharmaceutical said. Regardless, Avant is continuing to look into the claims, it said.

The lower royalty rate is 70%...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.